• Pill
  • Acute lymphoid leukemia
  • Philadelphia chromosome-positive
  • newly diagnosed
  • in combination with chemotherapy. Acute lymphoid leukemia
  • Relapsed/Refractory
  • Philadelphia chromosome-positive. Chronic eosinophilic leukemia. Chronic myeloid leukemia
Back to: Full Site NavigationSkip to: side effects sectionSkip to: What to expect sectionSkip to: Risks and warnings sectionSkip to: Tips from users and pharmacists
Skip Upsides & Downsides section. Skip to side effects section.
Lower-cost generic available

Save on your next Gleevec (Imatinib) prescription

Be sure you’re getting the lowest price for your medication, even if you have insurance.

Skip side effects sections. Skip to What to Expect and Pharmacists Tips section.

Side effects for Gleevec (Imatinib)

From clinical trials of Gleevec / Acute lymphoid leukemia ( 1425)

  • Neutropenia (<750/µl)Neutropenia (<750/µl)71% for imatinib vs.34% for placebo
  • Thrombocytopenia (<75,000/µl)Thrombocytopenia (<75,000/µl)55% for imatinib vs.51% for placebo
  • Hepatic (transaminase and/or bilirubin)Hepatic (transaminase and/or bilirubin)22% for imatinib vs.17% for placebo
  • InfectionInfection17% for imatinib vs.14% for placebo
  • Low blood potassiumLow blood potassium9% for imatinib vs.5% for placebo
  • Nausea and/or vomitingNausea and/or vomiting4% for imatinib vs.1% for placebo
  • Mouth and lip swellingMouth and lip swelling3% for imatinib vs.2% for placebo
  • Excessive bleedingExcessive bleeding2% for imatinib vs.1% for placebo
  • Loss of appetiteLoss of appetite2% for imatinib vs.1% for placebo
  • DiarrheaDiarrhea2% for imatinib vs.0% for placebo

Tips from pharmacists and people taking Gleevec (Imatinib)

Final section. Do you want to return to drug navigation?
The FDA category for this medication is D. It is advised that you: Weigh risks vs. benefits